JPH05502681A - 超音波エコグラフィーに適切な中空気体封入微小球の安定懸濁物の製造のための方法 - Google Patents
超音波エコグラフィーに適切な中空気体封入微小球の安定懸濁物の製造のための方法Info
- Publication number
- JPH05502681A JPH05502681A JP3514582A JP51458291A JPH05502681A JP H05502681 A JPH05502681 A JP H05502681A JP 3514582 A JP3514582 A JP 3514582A JP 51458291 A JP51458291 A JP 51458291A JP H05502681 A JPH05502681 A JP H05502681A
- Authority
- JP
- Japan
- Prior art keywords
- foam
- suspension
- viscosity
- air
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 36
- 239000004005 microsphere Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 41
- 238000002604 ultrasonography Methods 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 239000006260 foam Substances 0.000 claims abstract description 27
- 238000005187 foaming Methods 0.000 claims abstract description 23
- 239000000243 solution Substances 0.000 claims description 37
- 239000007788 liquid Substances 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 229920005862 polyol Polymers 0.000 claims description 7
- 150000003077 polyols Chemical class 0.000 claims description 7
- 229930091371 Fructose Natural products 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004925 denaturation Methods 0.000 claims description 6
- 230000036425 denaturation Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000010008 shearing Methods 0.000 claims description 6
- 238000005549 size reduction Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229920001100 Polydextrose Polymers 0.000 claims description 5
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 235000005822 corn Nutrition 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000001259 polydextrose Substances 0.000 claims description 5
- 229940035035 polydextrose Drugs 0.000 claims description 5
- 235000013856 polydextrose Nutrition 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 150000004676 glycans Polymers 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 239000011343 solid material Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 239000011147 inorganic material Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000011368 organic material Substances 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 150000004804 polysaccharides Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 235000020374 simple syrup Nutrition 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 239000007789 gas Substances 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 108091006905 Human Serum Albumin Proteins 0.000 description 13
- 102000008100 Human Serum Albumin Human genes 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 5
- -1 polyoxyethylene Polymers 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012460 protein solution Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 235000019890 Amylum Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RFSDQDHHBKYQOD-UHFFFAOYSA-N 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine Chemical compound C1=CC(O)=CC=C1NC1=NC(OCC2CCCCC2)=C(N=CN2)C2=N1 RFSDQDHHBKYQOD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000703769 Culter Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 101710169603 Hemoglobin-1 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 241000674789 Nicator Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101700004678 SLIT3 Proteins 0.000 description 1
- 102100027339 Slit homolog 3 protein Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000035780 glucosuria Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 108010014241 oxypolygelatine Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (18)
- 1.生体における超音波適用のために適切な空気もしくは気体封入微小球又は微 小中空球(該微小球は少なくとも1種類の膜形成タンパク質により覆われている )の安定なる水性懸濁物を調製するための方法であって、該タンパク質の粘性水 溶液を空気又は薬学的に受け入れられる気体と撹拌せしめることにより空気又は 気体か封入されている気泡の泡へと変換せしめ、そして同時に又はその後、該泡 における該気泡のサイズを注射に適切な約0.5〜10μmの範囲の値へと小さ くするために該発泡溶液を十分な時間をかけて、バッフル手段を任意的に含む狭 い開口部又は通路に押し通すことによって強い勇断にかけることを特徴とする方 法。
- 2.請求項1に記載の方法であって、外周上に平行に軸方向に並んでいるスリッ ト及び中央部に軸回転するカッターを有する管状ヘッドを含んで成るホモジナイ ザー並びに乳化装置において、前記の泡を強い剪断にかける方法(この作用は、 周辺の空気がこの液体と混合されること及びこの空気−液体混合物が該スリット に軸方向に押し通されることを引き起こし、これによって該泡は強い剪断作用に かけられる)。
- 3.請求項2に記載の方法であって、前記のホモジナイザー−乳化装置により発 生する熱によるタンパク質変性を回避するため、前記の発泡及び気泡サイズ縮小 の際の温度を50℃以下に保ち続ける方法。
- 4.請求項1に記載の方法であって、得られる前記の懸濁物が108〜109個 /mlの範囲における微小気泡の濃度を有す方法。
- 5.請求項1に記載の方法であって、前記の得られる懸濁を、生体の血流に直接 注射することを可能とするようなわずかなcPへとその粘度を下げるために水又 は生理学的に受け入れられる液体により更に希釈せしめる方法。
- 6.請求項5に記載の方法であって、前記の希釈溶液を、乾燥状態において無期 限にわたり変化することがなく且つ対応する量の水又は注射のために適切な生理 学的に受け入れられている液体と混合せしめることにより微小中空球の懸濁物を 再生せしめる固形物へと凍結乾燥せしめる方法。
- 7.請求項5に記載の方法であって、前記の希釈液が前記の希釈懸濁物の保存安 定性を高める物質、例えば有機アルデヒドを含んで成る方法。
- 8.請求項5に記載の方法であって、変性による膜タンパク質の硬化を及ぼすた めに前記の希釈溶液を数秒から数分間60〜120℃の温度に加熱することを含 んで成る方法。
- 9.請求項1に記載の方法であって、前記の泡に摩擦作用を提供する媒体、即ち 、多数のバッフル化通路を有す無機又は有機材料に該泡を押し通すことにより、 該泡を強い剪断にかける方法。
- 10.請求項4に記載の方法であって、タンパク質で覆れている前記の気泡の特 性を発展的な変性により改善せしめるため、得られる前記の懸濁物を数秒間から 数分間60〜120℃で更に加熱する方法。
- 11.請求項1に記載の方法により超音波エコグラフィーに適切な微小気泡の懸 濁物へと変換せしめた水性組成物であって、溶液中に膜形成タンパク質0.1〜 5重量%及び周囲温度粘度を約100〜600cPに迄高める水溶性ポリオール 粘度上昇剤40〜80重量%、並びに任意的に発泡上昇剤としての界面活性剤及 び該泡の安定性を高めるための架橋剤を含んで成ることを特徴とする組成物。
- 12.前記のポリオール粘度上昇剤が1分子当りに少なくとも4個のOH基を有 する、請求項11に記載の組成物。
- 13.前記の粘度上昇剤がポリアルコール、モノ−、ポリー及びオリゴサッカラ イド並びにその混合物から選ばれる、請求項12に記載の組成物。
- 14.前記の粘度上昇剤が、グルコース、フルクトース、マンノース、デキスト ロース、デキストラン、ポリデキストロース、糖分シロップ、コーンシロップ、 少なくとも4個のグリセロール単位を有するポリグリセロール及びその混合物よ り選ばれる、請求項13に記載の方法。
- 15.安定剤、例えばホルムアルデヒド又はグルタルアルデヒドが加えられてい る、請求項11に記載の組成物。
- 16.少なくとも4週間にわたり安定であることを特徴とする、請求項1に記載 の方法を実施することにより得られる微小気泡の懸濁物。
- 17.生体のエコグラフィー検査のための請求項16に記載の懸濁物の利用方法 であって、該懸濁物を生理学的に受け入れられる液体により希釈せしめてその粘 度を約2〜30cPに迄下げ、そしてこの状態においてこれを検査すべき該生体 の血流に注射せしめ、これにより該生体において反響的応答が発生できるように なる方法。
- 18.請求項16に記載の組成物であって、その安定性が、膜形成タンパク質の 硬化を及ぼすために数秒から数分間60〜120℃に更に加熱することによって 高められている組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90810768 | 1990-10-05 | ||
AT90810768.3 | 1990-10-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05502681A true JPH05502681A (ja) | 1993-05-13 |
JP3247374B2 JP3247374B2 (ja) | 2002-01-15 |
Family
ID=8205956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51458291A Expired - Fee Related JP3247374B2 (ja) | 1990-10-05 | 1991-09-13 | 超音波エコグラフィーに適切な中空気体封入微小球の安定懸濁物の製造のための方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5310540A (ja) |
EP (1) | EP0504340B1 (ja) |
JP (1) | JP3247374B2 (ja) |
AT (1) | ATE123953T1 (ja) |
AU (1) | AU635449B2 (ja) |
CA (1) | CA2068334C (ja) |
DE (1) | DE69110656T2 (ja) |
DK (1) | DK0504340T3 (ja) |
ES (1) | ES2074725T3 (ja) |
GR (1) | GR3017233T3 (ja) |
NO (1) | NO303965B1 (ja) |
WO (1) | WO1992005806A1 (ja) |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5656211A (en) | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US7083778B2 (en) | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6989141B2 (en) | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US5578292A (en) * | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US6613306B1 (en) | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US5562099A (en) * | 1990-10-05 | 1996-10-08 | Massachusetts Institute Of Technology | Polymeric microparticles containing agents for imaging |
GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
US5558857A (en) * | 1991-06-03 | 1996-09-24 | Nycomed Imaging As | Contrast agents |
GB9111880D0 (en) * | 1991-06-03 | 1991-07-24 | Unilever Plc | Forming minute gas cells in a liquid medium |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
RU2114637C1 (ru) * | 1991-09-17 | 1998-07-10 | Сонус Фармасьютикалз, Инк. | Биосовместимая контрастная среда и способ получения ультразвукового изображения |
MX9205298A (es) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) * | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
US5718884A (en) * | 1992-09-16 | 1998-02-17 | Nycomed Imaging As | Microbubble-based contrast agents with crosslinked and reduced proteinaceous shells |
GB9221329D0 (en) | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
CN1042190C (zh) * | 1992-12-02 | 1999-02-24 | 尤尼利弗公司 | 一种冷冻甜点心及其制备方法 |
JPH08503936A (ja) * | 1992-12-02 | 1996-04-30 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 化粧品組成物 |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
CZ191695A3 (en) * | 1993-01-25 | 1996-05-15 | Sonus Pharma Inc | Biologically compatible contrast agent, process of its preparation and representation method by ultrasound |
IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Colloids with phase difference as contrast ultrasound agents |
US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US5362478A (en) * | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US5578291A (en) * | 1993-05-14 | 1996-11-26 | The Board Of Regents Of The University Of Nebraska | Method and composition for optimizing left ventricular videointensity in echocardiography |
US5701899A (en) * | 1993-05-12 | 1997-12-30 | The Board Of Regents Of The University Of Nebraska | Perfluorobutane ultrasound contrast agent and methods for its manufacture and use |
US5567415A (en) * | 1993-05-12 | 1996-10-22 | The Board Of Regents Of The University Of Nebraska | Ultrasound contrast agents and methods for their manufacture and use |
US5695740A (en) * | 1993-05-12 | 1997-12-09 | The Board Of Regents Of The University Of Nebraska | Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide |
US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
ES2068151B1 (es) * | 1993-06-23 | 1995-11-16 | Cabrera Garrido Juan | Microespuma inyectable para esclerosis. |
AU722742B2 (en) * | 1993-07-02 | 2000-08-10 | Molecular Biosystems, Inc. | Methods for making encapsulated microspheres from heat denatured protein using mechanical cavitation |
US5855865A (en) * | 1993-07-02 | 1999-01-05 | Molecular Biosystems, Inc. | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas |
BR9406993A (pt) * | 1993-07-02 | 1996-09-10 | Molecular Biosystems Inc | Microesferas de gases insolúveis encapsulados com proteína e sua preparação e uso como agentes de imagem ultrassônica |
US5798091A (en) * | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
PT711179E (pt) * | 1993-07-30 | 2005-03-31 | Imcor Pharmaceutical Company | Composicoes de microbolhas estabilizadas para ultra-som |
DE69432295T2 (de) * | 1993-12-15 | 2003-08-14 | Bracco Research Sa | Gas-mischungen verwendbar als ultraschallkontrastmittel |
US5736121A (en) | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
US5730955A (en) * | 1994-08-02 | 1998-03-24 | Molecular Biosystems, Inc. | Process for making gas-filled microspheres containing a liquid hydrophobic barrier |
US5965109A (en) * | 1994-08-02 | 1999-10-12 | Molecular Biosystems, Inc. | Process for making insoluble gas-filled microspheres containing a liquid hydrophobic barrier |
US5562893A (en) * | 1994-08-02 | 1996-10-08 | Molecular Biosystems, Inc. | Gas-filled microspheres with fluorine-containing shells |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
TW404835B (en) * | 1994-10-05 | 2000-09-11 | Becton Dickinson Co | A viscoelastic dispersion composition |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
IL116328A (en) † | 1994-12-16 | 1999-09-22 | Bracco Research Sa | Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5625137A (en) * | 1995-05-25 | 1997-04-29 | Wisconsin Alumni Research Foundation | Very low scatter liquid and solid tissue mimicking material for ultrasound phantoms and method of making the same |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US5820850A (en) * | 1995-06-07 | 1998-10-13 | Molecular Biosystems, Inc. | Gas-filled amino acid block co-polymer microspheres useful as ultrasound contrast agents |
US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US5897851A (en) * | 1995-06-07 | 1999-04-27 | Sonus Pharmaceuticals, Inc. | Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging |
US5648098A (en) * | 1995-10-17 | 1997-07-15 | The Board Of Regents Of The University Of Nebraska | Thrombolytic agents and methods of treatment for thrombosis |
ATE266426T1 (de) * | 1996-03-05 | 2004-05-15 | Acusphere Inc | Mikroverkapselte fluorierte gase zur anwendung als bilderzeugende mittel |
EP0888054B1 (en) * | 1996-03-12 | 2003-09-03 | Board Of Regents Of The University Of Nebraska | Composition for the site specific delivery of a drug and a method of use |
US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
JP2001507207A (ja) | 1996-05-01 | 2001-06-05 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 化合物を細胞に送達する方法 |
US5976501A (en) * | 1996-06-07 | 1999-11-02 | Molecular Biosystems, Inc. | Use of pressure resistant protein microspheres encapsulating gases as ultrasonic imaging agents for vascular perfusion |
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
US5807970A (en) * | 1996-08-16 | 1998-09-15 | Becton, Dickinson And Company | Blood compatible, shear sensitive formulations |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
US6017310A (en) * | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
ES2189974T3 (es) | 1996-09-11 | 2003-07-16 | Imarx Pharmaceutical Corp | Procedimientos mejorados para la obtencion de imagenes de diagnostico usando un agente de contraste y un vasodilatador. |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6083484A (en) * | 1996-10-17 | 2000-07-04 | Molecular Biosystems, Inc. | Microparticles stabilized by polynuclear chromium complexes and their use as ultrasound contrast agents |
US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
GB9708246D0 (en) | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Improvements in or relating to ultrasound imaging |
WO1998048783A1 (en) * | 1997-04-30 | 1998-11-05 | Point Biomedical Corporation | Microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
HU230338B1 (hu) * | 1997-06-27 | 2016-02-29 | Abraxis Bioscience Llc | Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
US6548048B1 (en) * | 1998-04-28 | 2003-04-15 | Amersham Health As | Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents |
ES2203242T3 (es) * | 1998-12-23 | 2004-04-01 | Unilever N.V. | Emulsiones fluidas que contienen agua y aceite y que comprenden burbujas de gas. |
US6317623B1 (en) * | 1999-03-12 | 2001-11-13 | Medrad, Inc. | Apparatus and method for controlling contrast enhanced imaging procedures |
EP1180047B1 (en) | 1999-05-21 | 2005-09-07 | Mallinckrodt Inc. | Contrast media resuspension device |
GB9912356D0 (en) | 1999-05-26 | 1999-07-28 | Btg Int Ltd | Generation of microfoam |
EP1202670A4 (en) * | 1999-08-13 | 2004-11-10 | Point Biomedical Corp | HOLLOW MICROSPHERES WITH CONTROLLED FRAGILITY FOR MEDICAL USE |
EP1202671A4 (en) | 1999-08-13 | 2004-11-10 | Point Biomedical Corp | MICROPARTICLES USEFUL AS ULTRASONIC CONTRAST AGENTS FOR THE LYMPHATIC SYSTEM |
GB0028692D0 (en) | 2000-11-24 | 2001-01-10 | Btg Int Ltd | Generation of therapeutic microform |
ATE469639T1 (de) * | 2001-08-08 | 2010-06-15 | Dominguez Maria Antonia Garcia-Olmedo | Injizierbarer schaum und neue pharmazeutische anwendungen dafür |
US8512680B2 (en) | 2001-08-08 | 2013-08-20 | Btg International Ltd. | Injectables in foam, new pharmaceutical applications |
US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
US20030215394A1 (en) * | 2002-05-17 | 2003-11-20 | Short Robert E. | Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream |
US6919068B2 (en) * | 2002-05-17 | 2005-07-19 | Point Biomedical Corporation | Method of preparing gas-filled polymer matrix microparticles useful for echographic imaging |
US20040185108A1 (en) * | 2003-03-18 | 2004-09-23 | Short Robert E. | Method of preparing gas-filled polymer matrix microparticles useful for delivering drug |
WO2005048983A1 (en) | 2003-11-17 | 2005-06-02 | Btg International Limited | Methods of preparing a foam comprising a sclerosing agent |
US8048439B2 (en) | 2003-11-17 | 2011-11-01 | Btg International Ltd. | Therapeutic foam |
CA2554239C (en) | 2004-01-20 | 2015-05-12 | Sunnybrook And Women's College Health Sciences Centre | High frequency ultrasound imaging using contrast agents |
GB0509824D0 (en) | 2005-05-13 | 2005-06-22 | Btg Int Ltd | Therapeutic foam |
US8518069B2 (en) | 2005-09-07 | 2013-08-27 | Cabochon Aesthetics, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US9358033B2 (en) * | 2005-09-07 | 2016-06-07 | Ulthera, Inc. | Fluid-jet dissection system and method for reducing the appearance of cellulite |
US9011473B2 (en) | 2005-09-07 | 2015-04-21 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US9486274B2 (en) | 2005-09-07 | 2016-11-08 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
US10548659B2 (en) * | 2006-01-17 | 2020-02-04 | Ulthera, Inc. | High pressure pre-burst for improved fluid delivery |
US20080014627A1 (en) * | 2005-12-02 | 2008-01-17 | Cabochon Aesthetics, Inc. | Devices and methods for selectively lysing cells |
US7885793B2 (en) | 2007-05-22 | 2011-02-08 | International Business Machines Corporation | Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution |
US9248317B2 (en) | 2005-12-02 | 2016-02-02 | Ulthera, Inc. | Devices and methods for selectively lysing cells |
US8439940B2 (en) | 2010-12-22 | 2013-05-14 | Cabochon Aesthetics, Inc. | Dissection handpiece with aspiration means for reducing the appearance of cellulite |
GB0811856D0 (en) * | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
US11096708B2 (en) | 2009-08-07 | 2021-08-24 | Ulthera, Inc. | Devices and methods for performing subcutaneous surgery |
US9358064B2 (en) | 2009-08-07 | 2016-06-07 | Ulthera, Inc. | Handpiece and methods for performing subcutaneous surgery |
US10357450B2 (en) | 2012-04-06 | 2019-07-23 | Children's Medical Center Corporation | Process for forming microbubbles with high oxygen content and uses thereof |
JP2012246306A (ja) * | 2012-08-22 | 2012-12-13 | Btg Internatl Ltd | 注射可能な泡製剤および新規な医薬的適用 |
US10577554B2 (en) | 2013-03-15 | 2020-03-03 | Children's Medical Center Corporation | Gas-filled stabilized particles and methods of use |
US20180161741A1 (en) * | 2016-12-13 | 2018-06-14 | Vela Blend, Inc. | Food processing machine with liquid injection |
US11147890B2 (en) | 2017-02-28 | 2021-10-19 | Children's Medical Center Corporation | Stimuli-responsive particles encapsulating a gas and methods of use |
WO2020118271A1 (en) * | 2018-12-07 | 2020-06-11 | Nanovalent Pharmaceuticals, Inc. | Fibrin-targeted polymerized shell lipid microbubbles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3141641A1 (de) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Ultraschall-kontrastmittel und dessen herstellung |
DE3313947A1 (de) * | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
DE3324754A1 (de) * | 1983-07-06 | 1985-01-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | Ultraschallkontrastmittel sowie dessen herstellung |
IE61591B1 (en) * | 1987-12-29 | 1994-11-16 | Molecular Biosystems Inc | Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production |
US4957656A (en) * | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
US5154914A (en) * | 1990-03-12 | 1992-10-13 | Research Corporation Technologies, Inc. | Methods of diagnostic image analysis using lipophilic contrast agents |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
-
1991
- 1991-09-13 CA CA002068334A patent/CA2068334C/en not_active Expired - Lifetime
- 1991-09-13 JP JP51458291A patent/JP3247374B2/ja not_active Expired - Fee Related
- 1991-09-13 AT AT91915803T patent/ATE123953T1/de not_active IP Right Cessation
- 1991-09-13 AU AU84958/91A patent/AU635449B2/en not_active Ceased
- 1991-09-13 ES ES91915803T patent/ES2074725T3/es not_active Expired - Lifetime
- 1991-09-13 US US07/855,032 patent/US5310540A/en not_active Expired - Lifetime
- 1991-09-13 WO PCT/EP1991/001706 patent/WO1992005806A1/en active IP Right Grant
- 1991-09-13 EP EP91915803A patent/EP0504340B1/en not_active Expired - Lifetime
- 1991-09-13 DK DK91915803.0T patent/DK0504340T3/da active
- 1991-09-13 DE DE69110656T patent/DE69110656T2/de not_active Expired - Lifetime
-
1992
- 1992-06-04 NO NO922203A patent/NO303965B1/no not_active IP Right Cessation
-
1995
- 1995-08-30 GR GR950402342T patent/GR3017233T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0504340A1 (en) | 1992-09-23 |
WO1992005806A1 (en) | 1992-04-16 |
AU635449B2 (en) | 1993-03-18 |
US5310540A (en) | 1994-05-10 |
GR3017233T3 (en) | 1995-11-30 |
NO922203D0 (no) | 1992-06-04 |
NO303965B1 (no) | 1998-10-05 |
DE69110656T2 (de) | 1995-11-09 |
DK0504340T3 (da) | 1995-08-21 |
CA2068334A1 (en) | 1992-04-06 |
ES2074725T3 (es) | 1995-09-16 |
CA2068334C (en) | 1996-09-03 |
EP0504340B1 (en) | 1995-06-21 |
JP3247374B2 (ja) | 2002-01-15 |
AU8495891A (en) | 1992-04-28 |
NO922203L (no) | 1992-06-04 |
DE69110656D1 (de) | 1995-07-27 |
ATE123953T1 (de) | 1995-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05502681A (ja) | 超音波エコグラフィーに適切な中空気体封入微小球の安定懸濁物の製造のための方法 | |
JP2769077B2 (ja) | 診断イメージング剤およびその調製方法 | |
JP4592831B2 (ja) | 中空マイクロカプセルの製造 | |
US6110444A (en) | Gas-containing microcapsules useful as contrast agents for diagnostic imaging | |
US5855865A (en) | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas | |
JP2842453B2 (ja) | 生体内に注入可能な安定な微小泡懸濁液 | |
US5718884A (en) | Microbubble-based contrast agents with crosslinked and reduced proteinaceous shells | |
US5976501A (en) | Use of pressure resistant protein microspheres encapsulating gases as ultrasonic imaging agents for vascular perfusion | |
JPH0341168B2 (ja) | ||
HU219340B (en) | Method for imparting resistance against collapsing to gas filled microvesicles in aqueous suspension and method for producing contrast agents for echography in precursor form | |
JPH0443889B2 (ja) | ||
HU226007B1 (en) | Microballons filled with air or gas, coated with polymeric membrane, usable for diagnostic purposes, as well as process for producing same | |
US6264918B1 (en) | Hollow microcapsules for methods of ultrasound imaging | |
Wheatley et al. | Structural studies on stabilized microbubbles: development of a novel contrast agent for diagnostic ultrasound | |
JP2000507228A (ja) | マイクロパーティクル、その製造方法ならびに超音波診断への応用 | |
JPH08310971A (ja) | 超音波診断用造影剤 | |
Deng | Development and characterization of a contrast agent for diagnostic ultrasound: polymer-coated microcapsules | |
MXPA96002851A (en) | Preparation of microcapsules hue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081102 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |